GenVec, Inc.

(Public, NASDAQ:GNVC)

StocksHaven Investments profiles a clinical stage biopharmaceutical company developing gene-based therapeutic drugs and vaccines. Its lead product candidate, TNFerade biologic (TNFerade), is being developed for use in the treatment of cancer, and is currently undergoing Phase III trials which are expected to be completed by Q1 2010. In addition to its therapeutic product development programs, GenVec is working with collaborators to develop new applications for its technology through its vaccine development programs. The Company is developing a vaccine in animal health against foot-and-mouth disease and preventative vaccines for malaria, human immunodeficiency virus (HIV), respiratory syncytial virus, and Herpes Simplex Virus Type 2 (HSV-2). Surrounded by cash infusions through grants, mutual and institutional investors, multi-purpose products with billion dollar market potential, and an already flowing revenue stream – GenVec is one company you shouldn’t pass by.

About

Genvec

...

Yesterday, Genomic Health, Inc. (GHDX) announced that a number of leading U.S. surgeons ask for Genomic Health's Oncotype DX breast cancer assay at the time of surgery or biopsy, in an effort to provide patients with prompt, critical information about treatment options available at their maiden visit to an oncologist. Oncotype DX, the growth engine of the company, was launched in 2004. It is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In late May 2009, Genomic Health announced that more than 100,000 test results have been delivered in over 40 countries worldwide since the commercial launch of Oncotype DX. The assay analyzes the activity of 21 genes within a breast cancer patient's tumor to calculate an individualized result (Recurrence Score). Upon ...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Friday July 31, 2009

PennyOmega.com Stock Report!

**************************************************************

ICOP Digital, Inc. (Nasdaq:ICOP), an industry-leading company engaged in advancing digital surveillance technology solutions, announced today that the Company will host a teleconference on August 6, 2009, to review its second quarter 2009 financial information and results. The Company plans to file its 10-Q on Friday, August 7, 2009. ICOP is a leading provider of advanced digital video surveillance and management solutions.

Response Genetics Inc. (Nasdaq: RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, will announce the results of separate analyses of KRAS gene mutations and TS and RRM1 gene expression in non-small

...

On June 26, 2009, Genomic Health Inc (GHDX) reported that the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer recommended the usage of validated multigene assays, such as Oncotype DX, as an adjunct to standard measures in determining the benefits of chemotherapy for early-stage breast cancer patients.

We believe that these recommendations go a long way in expanding the scope of Oncotype DX further in breast cancer treatment in the European market.

As a reminder, Oncotype DX, backed by clinical evidence, has the ability to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit for early stage breast cancer patients. Since its launch in January 2004, Oncotype DX has been used in more than 100,000 patients in over 40 countries worldwide for breast cancer treatment planning. More than 90% of the U.S. insured lives are covered

...

Oncotype DX for Breast Cancer is Growth EngineGenomic Health Inc. (GHDX) is an oncology-based biotech company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The company's first product, Oncotype DX, is used for early stage breast cancer patients to predict the likelihood of cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit.Oncotype DX breast cancer assay, launched in January 2004, is the first and only multi-gene expression test commercially available that has clinical evidence validating its ability to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The assay is intended for newly diagnosed patients whose breast cancer is stage I or II, ...

There’s been so much stem cell news recently, I haven’t written a lot about the other major breakthrough area in medicine. That is, of course, RNA interference (RNAi). So I’d like to rectify that oversight.

For those of you who are not familiar with RNA interference, here’s what it is and how it works: DNA is, in a sense, the operating system software for our cells. As such, DNA does not directly interact with genes. It’s too important to risk corruption through unnecessary exposure. Instead, DNA operates by sending out chemical instructions. These instructions are in the form of complex RNA molecules. They are similar to double-stranded DNA, but are usually single stranded.

Basically, these extraordinarily complex RNA molecules control gene activity or expression. This is important because nearly all diseases are either caused or cured by the proteins produced by genes. You can, therefore, think of the ability to

...

RXi Pharmaceuticals, in which CytRx Corporation holds a 45% stake, has signed an agreement with the University of Massachusetts Medical School for an exclusive worldwide license to certain technology for the oral delivery of RNAi therapeutics. RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. This new agreement expands the delivery options and aids in delivery of RNAi therapies.

For those of you who are unfamiliar with RNAi, it is a naturally occurring mechanism for the regulation of gene expression that has the potential to be harnessed to selectively inhibit the activity of any human gene. It is believed that this inhibition may potentially treat human diseases by “turning-off” genes that lead to disease. Basically it’s like creating drugs specifically for YOU. We all know that everyone has different interactions with drugs. But

...

WaferGen Biosystems, Inc. (WGBS.OB), the California-based gene and stem cell research systems developer, announced today the signing of an exclusive distribution agreement with Euroclone S.p.A in Italy. Euroclone will distribute WaferGen’s SmartSlide™ Micro-Incubation System. WaferGen also signed a distributor agreement for SmartSlide with Takeda Rika Kogyo, Co. Ltd., of Japan. Both distributors serve cell biologists and stem cell researchers in the life science markets within their geographic areas.

WaferGen’s SmartSlide Micro-Incubation System is a unique family of integrated fluidics exchange micro-incubation products that work seamlessly with inverted microscopes. This breakthrough technology is enabling cell biology and stem cell researchers to conduct complex time-lapse imaging studies, to grow and work with stem cells and other difficult to cultivate cells. It allows researchers to pursue cutting-edge research topics that are not addressable with existing technology. As an example, the SmartSlide System will allow researchers to precisely control and vary oxygen, carbon dioxide,

...

Caliper Life Sciences, Inc. (NASDAQ: CALP) this week introduced its latest video-imaging system. The IVIS Kinetic system is designed to see activity at the molecular level through non-invasive means. It’s the latest in a long line of preclinical imaging systems, including high-sensitivity bioluminescence and fluorescence molecular. The main difference is the video capability. This additional capability, the company states in a news release, “will further advance cardiovascular, neurology, immunology and oncology distribution studies conducted.”

The IVIS system enhances analysis of gene expression, cellular pathways and the body’s response to drugs. The current and intended application of the imaging is to track speed of reaction with drug use in lab animals and any different behaviors in lab animals.

“The IVIS Kinetic imaging system provides a window for scientists to view biological events as they happen,” said Kevin Hrusovsky, Caliper Life Sciences president and CEO. “This system is another great example of how Caliper

...

RXi Pharmaceuticals (RXII) is a biopharmaceutical company working towards the development and commercialization of proprietary therapies based upon RNA interference (RNAi). RNAi is considered to be a significant advancement in the field. In 2002, the journal Science selected RNAi as the “Breakthrough of the Year”. The discovery team, which included Dr. Craig Mello, one of the founders of RXi, was awarded the 2006 Nobel Prize in Medicine.

It is believed that RNAi, which is a naturally occurring mechanism for the regulation of gene expression, can be used to selectively inhibit the activity of any human gene. RXi hopes to harness the ability to inhibit or “turn off” targeted genes that lead to the development of specific diseases. Founded by leading researchers in the RNAi field, the company hopes to identify leading compounds and move towards pre-clinical and clinical development programs in neurology, metabolic disease, oncology, and a number of other

...